SK bioscience Statistics

Total Valuation

SK bioscience has a market cap or net worth of KRW 3.22 trillion. The enterprise value is 2.08 trillion.

Market Cap	3.22T
Enterprise Value	2.08T

Important Dates

The next estimated earnings date is Monday, April 28, 2025.

Earnings Date	Apr 28, 2025
Ex-Dividend Date	n/a

Share Statistics

SK bioscience has 78.35 million shares outstanding. The number of shares has decreased by -0.28% in one year.

Current Share Class	n/a
Shares Outstanding	78.35M
Shares Change (YoY)	-0.28%
Shares Change (QoQ)	+0.17%
Owned by Insiders (%)	0.11%
Owned by Institutions (%)	3.98%
Float	25.81M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	15.67
PB Ratio	1.83
P/TBV Ratio	1.89
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-48.10
EV / Sales	10.34
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-11.33

Financial Position

The company has a current ratio of 11.69, with a Debt / Equity ratio of 0.12.

Current Ratio	11.69
Quick Ratio	10.82
Debt / Equity	0.12
Debt / EBITDA	n/a
Debt / FCF	-1.12
Interest Coverage	-98.48

Financial Efficiency

Return on equity (ROE) is -2.51% and return on invested capital (ROIC) is -3.27%.

Return on Equity (ROE)	-2.51%
Return on Assets (ROA)	-3.03%
Return on Invested Capital (ROIC)	-3.27%
Return on Capital Employed (ROCE)	-5.01%
Revenue Per Employee	204.57M
Profits Per Employee	-43.98M
Employee Count	984
Asset Turnover	0.10
Inventory Turnover	1.20

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -33.58% in the last 52 weeks. The beta is 1.19, so SK bioscience's price volatility has been higher than the market average.

Beta (5Y)	1.19
52-Week Price Change	-33.58%
50-Day Moving Average	47,889.00
200-Day Moving Average	52,093.50
Relative Strength Index (RSI)	29.24
Average Volume (20 Days)	365,333

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SK bioscience had revenue of KRW 201.30 billion and -43.27 billion in losses. Loss per share was -565.42.

Revenue	201.30B
Gross Profit	54.36B
Operating Income	-96.08B
Pretax Income	-63.76B
Net Income	-43.27B
EBITDA	-59.38B
EBIT	-96.08B
Loss Per Share	-565.42

Full Income Statement

Balance Sheet

The company has 1.34 trillion in cash and 205.09 billion in debt, giving a net cash position of 1.13 trillion or 14,484.04 per share.

Cash & Cash Equivalents	1.34T
Total Debt	205.09B
Net Cash	1.13T
Net Cash Per Share	14,484.04
Equity (Book Value)	1.72T
Book Value Per Share	22,380.48
Working Capital	1.37T

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -53.61 billion and capital expenditures -130.15 billion, giving a free cash flow of -183.76 billion.

Operating Cash Flow	-53.61B
Capital Expenditures	-130.15B
Free Cash Flow	-183.76B
FCF Per Share	-2,345.44

Full Cash Flow Statement

Margins

Gross margin is 27.00%, with operating and profit margins of -47.73% and -21.50%.

Gross Margin	27.00%
Operating Margin	-47.73%
Pretax Margin	-31.67%
Profit Margin	-21.50%
EBITDA Margin	-29.50%
EBIT Margin	-47.73%
FCF Margin	n/a

Dividends & Yields

SK bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.28%
Shareholder Yield	0.28%
Earnings Yield	-1.35%
FCF Yield	-5.71%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

SK bioscience has an Altman Z-Score of 9.57.

Altman Z-Score	9.57
Piotroski F-Score	n/a